OSE Immunotherapeutics has been granted a patent for humanized monoclonal antibodies targeting CD127, the alpha chain of the IL7 receptor. The patent covers therapeutic uses for inhibiting inflammation associated with the IL-7 signaling pathway by administering anti-human CD127 agents. GlobalData’s report on OSE Immunotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on OSE Immunotherapeutics, Personalized cancer vaccines was a key innovation area identified from patents. OSE Immunotherapeutics's grant share as of April 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.
Humanized monoclonal antibodies for inhibiting inflammation in il-7 pathway
A recently granted patent (Publication Number: US11926671B2) discloses a method for inhibiting inflammation associated with the interleukin-7 (IL-7) signaling pathway by administering a composition containing an anti-human CD127 agent to a patient in need. The anti-human CD127 agent includes specific sequences for the antibody light and heavy chains that bind to CD127, thereby inhibiting inflammation related to autoimmune diseases, allergic diseases, cancer, transplantation rejection, respiratory diseases, and chronic viral infections.
Furthermore, the method involves the use of a humanized monoclonal antibody that specifically binds to human CD127 with high affinity, preventing IL-7 receptor signaling induced by IL-7 without activating certain signaling pathways. The antibody or antigen-binding fragment recognizes specific epitopes on CD127, disrupting its interaction with cytokine receptors and inhibiting internalization. The long-lasting effect of the antibody on the immune response, along with its fast action within a week of administration, makes it a promising approach for managing inflammation associated with IL-7 signaling, as outlined in the patent claims.
To know more about GlobalData’s detailed insights on OSE Immunotherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
